Machina Capital S.A.S. Makes New Investment in Moderna, Inc. $MRNA

Machina Capital S.A.S. purchased a new stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) during the 3rd quarter, Holdings Channel reports. The firm purchased 4,244 shares of the company’s stock, valued at approximately $817,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Moderna during the 2nd quarter worth about $2,142,877,000. Theleme Partners LLP bought a new position in shares of Moderna in the 2nd quarter valued at about $564,272,000. Wellington Management Group LLP increased its position in shares of Moderna by 4.4% in the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after acquiring an additional 103,977 shares during the last quarter. Merck & Co. Inc. acquired a new stake in shares of Moderna in the second quarter valued at about $161,642,545. Finally, Bamco Inc. NY acquired a new stake in shares of Moderna in the second quarter valued at about $139,317,000. 75.33% of the stock is owned by institutional investors.

Insider Activity

In other news, President Stephen Hoge sold 39,145 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the completion of the sale, the president directly owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 197,251 shares of company stock valued at $33,875,904 over the last three months. Insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on MRNA. Piper Sandler reissued an “overweight” rating and set a $305.00 price target (up from $230.00) on shares of Moderna in a research report on Monday, November 9th. William Blair cut Moderna from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 27th. Brookline Capital Markets reiterated a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Bradesco Corretora raised Moderna to an “outperform” rating in a report on Friday, August 28th. Finally, UBS Group reissued a “neutral” rating on shares of Moderna in a research note on Tuesday, September 22nd. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average target price of $113.75.

View Our Latest Report on MRNA

More Moderna News

Investors following MRNA have been watching these news items:

  • Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
  • Positive Sentiment: The company highlighted progress in its oncology pipeline, including its personalized cancer vaccine, positioning cancer treatments as a potential longer-term growth driver. Article
  • Neutral Sentiment: Moderna is scheduled to join the MSCI World Index in November, which could broaden its investor reach. It also reported peer-reviewed real-world data on its mNEXSPIKE COVID-19 vaccine in older adults; the reports provided limited detail on the potential commercial impact. Article

Moderna Price Performance

Shares of MRNA stock opened at $223.37 on Monday. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $280.80. The stock has a market cap of $90.38 billion, a price-to-earnings ratio of -31.46 and a beta of 1.16. The firm’s 50-day moving average is $201.67 and its 200-day moving average is $96.41. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. Moderna’s quarterly revenue was up 29.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.51) earnings per share. Sell-side analysts predict that Moderna, Inc. will post -5.14 EPS for the current year.

About Moderna

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Featured Articles

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.